Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 8.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,960 shares of the company’s stock after buying an additional 1,945 shares during the quarter. Russell Investments Group Ltd. owned 0.05% of Mirum Pharmaceuticals worth $1,073,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Jones Financial Companies Lllp boosted its position in shares of Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock worth $30,000 after buying an additional 357 shares during the period. R Squared Ltd purchased a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $69,000. AlphaQuest LLC lifted its position in shares of Mirum Pharmaceuticals by 969.6% during the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock worth $76,000 after purchasing an additional 1,658 shares in the last quarter. Avanza Fonder AB purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $189,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $277,000.

Mirum Pharmaceuticals Trading Down 1.8 %

MIRM opened at $38.39 on Tuesday. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -19.00 and a beta of 1.00. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $54.23. The business’s 50 day moving average is $44.98 and its two-hundred day moving average is $44.01. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The business had revenue of $99.41 million for the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. On average, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 6,837 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $327,629.04. Following the completion of the transaction, the chief executive officer now owns 125,022 shares in the company, valued at approximately $5,991,054.24. This represents a 5.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $43,223.84. Following the completion of the sale, the senior vice president now directly owns 3,524 shares in the company, valued at approximately $168,870.08. The trade was a 20.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 116,473 shares of company stock worth $5,249,134 in the last quarter. Company insiders own 22.87% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on MIRM shares. HC Wainwright boosted their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $58.20.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.